IL-6 KD in anti-CD19 CAR T cells against Burkitt’s Lymphoma resulted in no objective neurotoxicity, immunotoxicity, or tumorigenicity, while retaining the anti-tumor cytotoxicity and production of other cytokines. Here, CD19 is linked to neoplasm.